Navigation Links
Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
Date:5/28/2008

LEBANON, N.J., May 28 /PRNewswire/ -- Orphan Therapeutics today announced that it has begun submission of the rolling LUCASSIN(R) (terlipressin) New Drug Application (NDA) for the treatment of hepatorenal syndrome (HRS) type 1 in patients with late-stage liver cirrhosis. LUCASSIN(R) had previously been granted orphan status and fast track designation for this indication by the U.S. Food and Drug Administration (FDA). Currently no drug is approved in the U.S. to treat HRS type 1, a rare and life-threatening condition in late-stage liver disease.

The LUCASSIN(R) rolling NDA submission is based on the results from OT-0401,(1) a randomized, double-blind, multi-center, placebo-controlled Phase III study in 112 patients with HRS type 1 conducted by Orphan Therapeutics, and is independently supported by TAHRS,(2) a second randomized, multi-center, controlled study in 46 patients coordinated by the University of Barcelona. Orphan Therapeutics holds exclusive rights to the TAHRS data for the NDA submission.

"We are pleased to report that, coinciding with the start of our rolling NDA for LUCASSIN(R), the two HRS studies, OT-0401 and TAHRS, have been published in the May 2008 issue of Gastroenterology," said Peter Teuber, president of Orphan Therapeutics. "I would like to thank all authors, investigators and members of the LUCASSIN(R) team for their contributions to these two landmark trials, which together represent the largest number of HRS patients studied in a randomized and controlled study design to-date."

The rolling submission process enables companies that have been granted fast track designation to submit sections of the NDA to the FDA as they become available. The FDA grants fast track status to drug candidates that treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Terlipressin received orphan drug designation in October 2004 and fast track status in April 2005 for treatment of
'/>"/>

SOURCE Orphan Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
2. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
3. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
4. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
5. Historic Global Vigil for AIDS Orphans Ends in New York City
6. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
7. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
8. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
9. AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
10. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
11. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2008 Financial Results on Wednesday, May 14, 2008 at 4:30 P.M. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Cell ... The report then explores global and China’s top ... capacity, Production value, and market share etc. The ...
(Date:8/30/2014)... Hundreds of Byetta lawsuits ( http://www.byettalawsuit.com ... forward in U.S. courts, Bernstein Liebhard LLP reports. According ... 31, 2014, Byetta and Bydureon (an extended-release version of ... that allege the drugs caused pancreatitis, pancreatic cancer and ... claims are pending in a multidistrict litigation underway in ...
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... The diagnosis of multiple sclerosis using the magnetic resonance ... the new findings// published by the BMJ. ... the National Institute for Health and Clinical Excellence (NICE) ... sclerosis. Although its accuracy has been assessed, the evidence ...
... ministry have denied the presence of any bird flu infection ... flu,' said Jose Angel del Valle, the ministry's animal health ... in the U.S. commodities markets, leading to a reduction in ... the death of a duck, in the town of Nogales, ...
... government will donate $35,700 to a clinic here ... ,The donation, in Australian dollars, was announced ... ,"The donation again demonstrates the Australian ... she said. ,"By funding this clinic, ...
... of Health in China has revealed that just over 67 ... HIV/AIDS//. ,This survey was conducted recently by a research ... from 1,919 respondents in 24 colleges of 19 cities.,The results ... aware of how HIV/AIDS is transmitted and 75.6 per cent ...
... non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs, ... NEXIUM? (esomeprazole magnesium). // These results were from ... the April 2006 edition of the American Journal ... such as ibuprofen, naproxen and aspirin, and newer ...
... Nitish Kumar is all for a giving a boost to ... tomato and green vegetables// at their official residence, he wants ... farming. ,Nitish Kumar comes from a family with ... practitioner in his home district of Nalanda. Even today Nitish's ...
Cached Medicine News:Health News:MRI Scan Insufficient For Diagnosing Multiple Sclerosis 2Health News:Patients on NSAIDS have reduced gastric ulcers risk by Nexium? 2
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... North America Aesthetic Lasers and Energy ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America Aesthetic ... Summary GlobalData,s new report, "North America ... 2020", provides key market data on the North ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... The Blumenthal,Cancer Center at Carolinas Medical Center (CMC) ... in a study that could lead to individualized,treatments ... first hospital system,outside Moffitt,s home state of Florida ... CMC will enroll more than 2,300 patients in,the ...
... PCOP ), an innovator in the discovery and ... completion of recruitment,in the company,s multi-center Phase 2a ... product candidate. The objective of the Phase,2a randomized, ... and safety of 200 and 500 mg of ...
Cached Medicine Technology:CMC, Moffitt Partner to Study Cancer 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 4
... TheraSeed® Pd-103 implant is a combination of ... visibility that makes TheraSeed® treatment an ideal ... be confident that every TheraSeed® implant order ... which is required by clinicians who must ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Medicine Products: